Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA

Published: Monday, October 21, 2013
Last Updated: Monday, October 21, 2013
Bookmark and Share
IMAB362 receives orphan drug designation for the treatment of pancreatic cancer.

Ganymed Pharmaceuticals AG has announced that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan drug designation to IMAB362 for the treatment of pancreatic cancer.

IMAB362 is a monoclonal antibody currently in Phase IIb clinical trial for gastroesophageal cancer.

“The granting of this orphan drug designation represents another important milestone for our IMAB362 program”, commented Dr. Özlem Türeci, CEO of Ganymed Pharmaceuticals.

Dr. Türeci continued, “There are presently very few therapeutic options for patients suffering from pancreatic cancer. We are excited by the promise that IMAB362 showed in preclinical models of pancreatic cancer and look forward to assessing its therapeutic potential in future clinical trials for this indication.”

Orphan drug designation is given to investigational new drugs that are under development for the treatment of life-threatening or very serious diseases that affect fewer than 200,000 patients in the US or less than 5 in 10,000 individuals across Europe.

The designation aims to promote the development of innovative drugs for patients with these rare diseases by incentivizing companies with certain benefits such as market exclusivity, tax incentives and waiving of certain regulatory and marketing fees.

IMAB362 is a first-in-class monoclonal antibody selectively binding to the tight junction protein CLDN18.2 which is expressed in approximately 60% of primary and metastatic pancreatic cancers.

CLDN18.2 is also expressed in up to 80% of gastroesophageal cancers as well as in other solid tumors. However, CLDN18.2 is absent from the vast majority of healthy tissues.

This makes IMAB362 cancer cell selective with little or no effect on healthy cells and reduced risks of side effects. This represents a great advantage over other anticancer therapies which target both cancerous and healthy cells.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ganymed's IMAB362 Extends Survival in Gastric Cancer
IMAB362 nearly doubles survival in patients with the highest levels of Claudin18.2 to develop high target immunotherapy against cancer.
Tuesday, June 07, 2016
Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer
Second antibody from Ganymed’s ideal monoclonal antibody platform in the clinic.
Thursday, February 13, 2014
Ganymed Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Conference will take place from January 13 to January 16, 2014 in San Francisco.
Thursday, December 26, 2013
Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round
Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer.
Monday, November 18, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!